Sign In

Adam Fein

CEO, Drug Channels Institute

Adam J. Fein, Ph.D., is the President of the Drug Channels Institute (DCI), a company under HMP Global that specializes in pharmaceutical economics and the complexities of pharmacy distribution and reimbursement systems. He is recognized as one of the leading experts in the pharmaceutical industry, having published extensively in both academic and industry circles, and is frequently cited in major publications such as The Wall Street Journal and The New York Times .14

Dr. Fein created the influential Drug Channels website, which serves as a comprehensive resource for industry analysis, often delivered with a humorous touch. This platform covers various topics including pharmacy economics, drug pricing, and the roles of pharmacy benefit managers (PBMs) .13 He holds a Ph.D. in Managerial Science and Applied Economics from the Wharton School of Business at the University of Pennsylvania and a B.A. in Economics from Brandeis University .25

In addition to his role at DCI, Dr. Fein has been involved in various consulting capacities and serves on advisory boards for organizations within the pharmaceutical sector. He is also known for hosting events like the Drug Channels Leadership Forum, where he engages with industry leaders to discuss pressing issues facing the pharmaceutical market .46 Dr. Fein resides in Philadelphia with his wife, Paula Fein, who is also involved in DCI as Vice President of Business Development .12

Highlights

Jan 27 · twitter

𝐃𝐫𝐮𝐠 𝐂𝐡𝐚𝐧𝐧𝐞𝐥𝐬 𝐍𝐞𝐰𝐬 𝐑𝐨𝐮𝐧𝐝𝐮𝐩, 𝐉𝐚𝐧𝐮𝐚𝐫𝐲 2026: 𝐂𝐮𝐛𝐚𝐧 𝐯𝐬. 𝐎𝐩𝐭𝐮𝐦, 𝐌𝐜𝐊𝐞𝐬𝐬𝐨𝐧’𝐬 𝐁𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫 𝐏𝐥𝐚𝐲, 𝐒𝐭𝐚𝐭𝐞𝐬 𝐯𝐬. 𝐀𝐜𝐜𝐮𝐦𝐮𝐥𝐚𝐭𝐨𝐫𝐬, 340𝐁 𝐖𝐢𝐧𝐝𝐟𝐚𝐥𝐥𝐬, 𝐚𝐧𝐝 𝐎𝐳𝐞𝐦𝐩𝐢𝐜 𝐀𝐝𝐬

A pre-Super Bowl playbook of what mattered this month in pharmaceutical channels: ✅ Mark Cuban @mcuban takes on Optum’s Patrick Conway in a fiery debate ✅ @McKesson makes its private-label biosimilar move ✅ State anti-accumulator laws keep gaining ground ✅ #340B hospitals are still specialty drug profiteers ✅ Plus: Will Ozempic's new ad campaign make us nostalgic for 2006?

🏈 A fan-favorite roundup before kickoff 👇 https://t.co/G6qM4BwI67

Jan 26 · twitter

𝐑𝐨 𝐚𝐧𝐝 𝐭𝐡𝐞 𝐍𝐞𝐭 𝐏𝐫𝐢𝐜𝐢𝐧𝐠 𝐃𝐫𝐮𝐠 𝐂𝐡𝐚𝐧𝐧𝐞𝐥

Thoughtful @WSJ piece from @andykessler about Ro and its direct-to-patient, low list price model for GLP-1s and other drugs.

That’s exactly the logic behind the 𝐍𝐞𝐭 𝐏𝐫𝐢𝐜𝐢𝐧𝐠 𝐃𝐫𝐮𝐠 𝐂𝐡𝐚𝐧𝐧𝐞𝐥 (#NPDC). PBM's power loses much of its practical force when patients—or their plans—can access a product at a visible, low net price.

The NPDC won't work for every drug, but it can begin to deflate the gross-to-net bubble

Full article: https://t.co/wig39tjXAU

#DrugPricing #NetPricingDrugChannel #Healthcare

Related Questions

What are some of Adam Fein's most influential articles or reports?
How did Adam Fein start his career in pharmaceutical economics?
What makes the Drug Channels website unique compared to other industry publications?
How does Adam Fein incorporate humor into his industry analysis?
What are some key trends Adam Fein has identified in the pharmaceutical industry?
Adam Fein
Adam Fein, photo 1
Adam Fein, photo 2
Add to my network

Location

Philadelphia, Pennsylvania, United States